October 31, 2019

Stephen From
President and Chief Executive Officer
EyeGate Pharmaceuticals, Inc
271 Waverley Oaks Road, Suite 108
Waltham, MA 02452

       Re: EyeGate Pharmaceuticals, Inc.
           Registration Statement of Form S-3
           Filed October 18, 2019
           File No. 333-234255

Dear Mr. From:

       We have limited our review of your registration statement to those
issues we have
addressed in our comment. In our comment, we may ask you to provide us with
information so
we may better understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comment applies to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to the comment, we may have additional comments.

Registration Statement of Form S-3 filed October 18, 2019

Exhibits

1.     We refer to Article V.E of your Restated Articles of Incorporation filed
as Exhibit 3.1.
       Your forum selection provision identifies the Court of Chancery of the
State of Delaware
       as the exclusive forum for certain litigation, including any "derivative
action." Please
       disclose whether this provision applies to actions arising under the
Securities Act or
       Exchange Act. In that regard, we note that Section 27 of the Exchange
Act creates
       exclusive federal jurisdiction over all suits brought to enforce any
duty or liability created
       by the Exchange Act or the rules and regulations thereunder, and Section
22 of the
       Securities Act creates concurrent jurisdiction for federal and state
courts over all suits
       brought to enforce any duty or liability created by the Securities Act
or the rules and
       regulations thereunder. If the provision applies to Securities Act
claims, please also revise
 Stephen From
EyeGate Pharmaceuticals, Inc
October 31, 2019
Page 2
      your prospectus to state that there is uncertainty as to whether a court
would enforce such
      provision and that investors cannot waive compliance with the federal
securities laws and
      the rules and regulations thereunder. If this provision does not apply to
actions arising
      under the Securities Act or Exchange Act, please tell us how you will
inform investors in
      future filings that the provision does not apply to any actions arising
under the Securities
      Act or Exchange Act.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

      Please contact Folake Ayoola at (202) 551-3673 or Christine Westbrook at
(202) 551-
5019 with any other questions.



                                                            Sincerely,
FirstName LastNameStephen From
                                                            Division of
Corporation Finance
Comapany NameEyeGate Pharmaceuticals, Inc
                                                            Office of Life
Sciences
October 31, 2019 Page 2
cc:       Stephen D. Brook, Esq.
FirstName LastName